Ferroptosis is a newly discovered cell death pathway driven by iron-dependent lipid peroxidation. We recently discovered new inducers of ferroptosis, and specific metabolic states that increase vulnerability to ferroptosis, and thus can be used for cancer therapy. We have multidisciplinary projects related to ferroptosis in TNBC, and we are currently looking for two talented and enthusiastic postdocs to join us.
Triple negative breast cancer (TNBC) is a highly aggressive disease that affects young women and currently has no effective treatment. The goal of our studies is to identify new therapeutic strategies for this particular subtype of breast cancer. Synthetic lethality is a powerful approach to selectively eliminate vulnerable cancer cells, and thus can be exploited for cancer therapy. Many studies including our own indicate that synthetic lethality screens could be a promising approach to identify novel drug targets for TNBC. A postdoctoral position is available to establish a genome-wide synthetic lethal screen to identify potent combination therapies for TNBC subtypes.
BRD4 (Bromodomain protein 4), a member of the BET (bromodomain and extra terminal domain) family, is an epigenetic reader that plays important roles in chromatin remodeling and transcriptional regulation. It is involved in cancer progression, metastasis and inflammatory diseases and is considered as promising therapeutic targets for different cancer subtypes, including TNBC. Targeting of BRD4 in TNBC and overcoming drug resistance are current questions that we address.
Ferroptosis is a newly discovered cell death pathway driven by iron-dependent lipid peroxidation. We recently discovered new inducers of ferroptosis, and specific metabolic states that increase vulnerability to ferroptosis, and thus can be used for cancer therapy. We have multidisciplinary projects related to ferroptosis in TNBC, and we are currently looking for a talented and enthusiastic postdoc to join us.
Triple negative breast cancer (TNBC) is a highly aggressive disease that affects young women and currently has no effective treatment. The goal of our studies is to identify new therapeutic strategies for this particular subtype of breast cancer. Synthetic lethality is a powerful approach to selectively eliminate vulnerable cancer cells, and thus can be exploited for cancer therapy. Many studies including our own indicate that synthetic lethality screens could be a promising approach to identify novel drug targets for TNBC. A postdoctoral position is available to establish a genome-wide synthetic lethal screen to identify potent combination therapies for TNBC subtypes.
Small extracellular vesicles (sEVs) or “exosomes” are secreted for all cell types and play critical role in cell-cell communication. In cancer, sEVs are involved in metastasis and can confer drug resistance. We recently showed that sEVs can be used as an excellent tool for early detection of breast cancer and for monitoring drug response. A postdoctoral position is available to investigate exosomes biology in cancer.
